Anthony Mato,


Director, Chronic Lymphocytic Leukemia Program
Associate Attending, Memorial Sloan Kettering Cancer Center
New York, NY

Anthony R Mato, MD, MSCE, is Associate Member at Memorial Sloan Kettering Cancer Center and Director of Chronic Lymphocytic Leukemia (CLL) Program at MSKCC. He received his medical degree from the State University of New York (SUNY) at Buffalo, and completed his residency in internal medicine and fellowship in hematology/oncology at the Hospital of the University of Pennsylvania. Dr Mato also earned a master’s degree in clinical epidemiology from the University of Pennsylvania School of Medicine. His research focuses on the development of clinical and translational trials for patients with CLL and lymphoproliferative disorders with a particular focus on novel immunotherapies, signal transduction inhibitors, immune checkpoint inhibitors, and immunotherapy agents. He focuses on outcomes research for CLL patients with a focus on outcomes in the real world setting. He has been the principal investigator on several clinical trials for patients with CLL and currently has multiple clinical trials that are open to accrual and enrolling patients actively. Dr Mato has authored or coauthored several articles that have been published in peer-reviewed journals including Blood, British Journal of Hematology, Annals of Oncology, Heamatologica, Lancet Oncology, and American Journal of Hematology. He is a member of the American Society of Clinical Oncology, American Society of Hematology, and American College of Physician Executives. He is on the medical advisory board of the CLL Society.